Intrahepatic Cholangiocarcinoma Clinical Trials

33 recruiting

Intrahepatic Cholangiocarcinoma Trials at a Glance

55 actively recruiting trials for intrahepatic cholangiocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 36 trials, with the heaviest enrollment activity in Shanghai, Chengdu, and Houston. Lead sponsors running intrahepatic cholangiocarcinoma studies include Fudan University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, and City of Hope Medical Center.

Browse intrahepatic cholangiocarcinoma trials by phase

Treatments under study

About Intrahepatic Cholangiocarcinoma Clinical Trials

Looking for clinical trials for Intrahepatic Cholangiocarcinoma? There are currently 33 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Intrahepatic Cholangiocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Intrahepatic Cholangiocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 55 trials

Recruiting
Phase 2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 2

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Intrahepatic Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center164 enrolled11 locationsNCT04891289
Recruiting
Phase 2

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

CholangiocarcinomaBile Duct CancerCholangiocarcinoma Non-resectable+2 more
Beth Israel Deaconess Medical Center30 enrolled1 locationNCT05655949
Recruiting
Phase 1Phase 2

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma+3 more
Mayo Clinic85 enrolled1 locationNCT03942328
Recruiting
Phase 2

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled2 locationsNCT06728410
Recruiting
Not Applicable

Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy

Intrahepatic CholangiocarcinomaLocally Advanced Intrahepatic Cholangiocarcinoma
Assistance Publique - Hôpitaux de Paris36 enrolled1 locationNCT06910722
Recruiting

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

CholangiocarcinomaHepatocellular CarcinomaHepatic Carcinoma+4 more
City of Hope Medical Center400 enrolled5 locationsNCT06342414
Recruiting

Liver Transplantation in Intrahepatic Cholangiocarcinoma

Intrahepatic CholangiocarcinomaCholangiocarcinoma, Intrahepatic
Rutgers, The State University of New Jersey30 enrolled2 locationsNCT06140134
Recruiting
Phase 1

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Intrahepatic CholangiocarcinomaGallbladder CarcinomaMetastatic Malignant Neoplasm in the Peritoneum+5 more
City of Hope Medical Center12 enrolled1 locationNCT05285358
Recruiting
Phase 2

HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center60 enrolled1 locationNCT06858735
Recruiting
Not Applicable

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Intrahepatic CholangiocarcinomaHepato Cellular Carcinoma (HCC)
University Hospital, Angers206 enrolled14 locationsNCT06990659
Recruiting
Phase 2

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Intrahepatic Cholangiocarcinoma (Icc)HAICDurvalumab
West China Hospital25 enrolled1 locationNCT06859684
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal NeoplasmsIntrahepatic Cholangiocarcinoma (Icc)Metastatic Colorectal Cancer (Mcrc)+1 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 2

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Liver CancerLiver MetastasesIntrahepatic Cholangiocarcinoma+1 more
Stanford University62 enrolled1 locationNCT07223307
Recruiting
Phase 2

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

Colorectal Cancer MetastaticIntrahepatic Cholangiocarcinoma
Michael J Cavnar, MD80 enrolled1 locationNCT07201519
Recruiting
Phase 2

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)

Chemotherapy EffectIntrahepatic Cholangiocarcinoma
Oslo University Hospital39 enrolled1 locationNCT06313203
Recruiting

Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers

Gall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)
Tata Memorial Centre60 enrolled1 locationNCT07337850
Recruiting
Phase 2Phase 3

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Solid Tumor, AdultAdvanced Intrahepatic Cholangiocarcinoma
Hutchmed235 enrolled1 locationNCT04353375
Recruiting
Not Applicable

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN

Neuroendocrine TumorsHepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)
Nantes University Hospital60 enrolled2 locationsNCT06735560
Recruiting
Phase 2

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Intrahepatic Cholangiocarcinoma (Icc)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University38 enrolled1 locationNCT06925516